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Abstract
Introduction: Natalizumab is a new humanized monoclonal antibody used in
multiple sclerosis (MS). The aim of this meta-analysis was to evaluate the efficacy
and tolerability of this drug in relapsing MS. PubMed, Scopus, Web of Science,
and Cochrane Central Register of Controlled Trials were searched for studies
that investigated the efficacy and/or tolerability of natalizumab in MS. Data
were collected from 1966 to 2008 (up to October).
Material and methods: The search terms were: “multiple sclerosis” or “MS” and
“natalizumab”. “Mean change in Expanded Disability Status Scale (EDSS)”,
“number of patients with at least one relapse”, and “number of patients with
at least one new gadolinium (Gd)-enhancing lesion” were the key outcomes of
interest for assessment of efficacy. “Any adverse events”, “serious adverse
events”, “death”, and “withdrawal because of adverse events” were the key
outcomes for tolerability. Among existing trials, four randomized placebo
controlled clinical trials met our criteria and were included.
Results: Pooled relative risk for at least one relapse in four trials including all doses
was 0.7, with a non-significant RR (95% CI: 0.42-1.17, p = 0. 17). Summary RR for at
least one relapse in two trials in which doses of 3 mg/kg or 6 mg/kg or 300 mg every
4 weeks were administered gave a value of 0.5 asa significant RR (95% CI: 0.42-0.61,
p < 0.0001). The summary RR for at least one new Gd-enhancing lesion was 0.22,
a non-significant RR (95% CI: 0.05-1.01, p = 0.051). Three deaths were reported in
the natalizumab group. Comparing adverse events between natalizumab and placebo
yielded a non-significant RR of 0.99 (95% CI: 0.96-1.01, p = 0.34) for any adverse
events (n = 3), and a significant RR of 0.39 (95% CI: 0.29-0.52, p < 0.0001) for serious
adverse events (n = 2). The summary RR for withdrawal due to adverse events by
natalizumab vs. placebo therapy between two trials was 1.43, a non-significant RR
(95% CI: 0.68-3.02, p = 0.35).
Conclusions: It seems that using 3 or 6 mg/kg every 4 weeks is the best method
of administration of natalizumab for preventing relapse and occurrence of new
Gd-enhancing lesions. The current data on the efficacy and safety of natalizumab
are insufficient to reach a convincing conclusion and thus further clinical trials
are still needed.
Key words: relapsing multiple sclerosis, natalizumab, efficacy, adverse events,
withdrawal, meta-analysis.
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Introduction
Multiple sclerosis (MS) is a chronic autoimmune
inflammatory disease of the central nervous system.
Although the exact aetiology of MS remains unclear,
it is likely caused by dysregulation of the immune
system leading to injury of the nervous system
which is triggered through a multifactorial pathway
of genetic predisposition and environmental triggers
(e.g. geographic latitude, vitamin D deficiency,
viruses, and smoking) [1, 2]. With an age onset of
20-40, overall incidence rate of MS is 3.6 cases per
100,000 person-years in women and 2.0 in men [3]. 
Several therapeutic options are available for MS
including interferon beta, glatiramer acetate,
immunomodulators, mitoxantrone, and monoclonal
antibodies (MAbs). The MAbs, as monospecific
antibodies against certain pro inflammatory/
inflammatory molecules, are currently used in many
autoimmune disorders and have shown great
potential for treatment of MS [4]. 
The α4β1 integrin is a cell adhesion molecule on
the surface of lymphocytes and monocytes that
mediates adherence and migration of leukocytes
through the blood brain barrier. Natalizumab,
a humanized monoclonal antibody, binds to α4
integrins and inhibits the integrin-induced
inflammatory pathway [5, 6].
Following Food and Drug Administration (FDA)
approval of natalizumab for treatment of MS in
November 2004, it was withdrawn from the market
in February 2005 because two patients who
received natalizumab in combination with
interferon-β1a developed progressive multifocal
leukoencephalopathy (PML) with one death [7, 8].
Natalizumab was conditionally re-approved in June
2006 after no additional cases of PML were
reported. Current guidelines recommend reserving
natalizumab for patients with aggressive initial
presentation or refractory to other therapies. In
addition, use of natalizumab in combination with
interferon is discouraged [9].
Until this time, no meta-analysis on the efficacy
and/or tolerability of natalizumab in relapsing MS
has been conducted. In the present work, by
evaluating all randomized controlled trials a meta-
analysis was conducted to reach a better conclusion
about the efficacy and tolerability of this new
promising medication for MS.
Material and methods
Data sources 
PubMed, Scopus, Web of Science, and Cochrane
Central Register of Controlled Trials were searched
for studies investigated the efficacy and/or
tolerability of natalizumab in multiple sclerosis. Data
were collected from 1966 to 2008 (up to October).
The search terms were: “multiple sclerosis” or “MS”
and “natalizumab”. The language was restricted to
English. The reference list from retrieved articles
was also reviewed for additional applicable studies.
Study selection
Controlled trials investigating the efficacy and/or
tolerability of natalizumab in patients with MS were
considered. “Mean change in Expanded Disability
Status Scale (EDSS)”, “number of patients with at
least one relapse”, and “number of patients with
at least one new gadolinium (Gd)-enhancing lesion”
were the key outcomes of interest for assessment
of efficacy. “Any adverse events”, “serious adverse
events”, “death”, and “withdrawal because of
adverse events” were the key outcomes for
tolerability. We evaluated all published studies as
well as abstracts presented at meetings. Three
reviewers independently examined the title and
abstract of each article to eliminate duplicates,
reviews, case studies, and uncontrolled trials. Trials
were disqualified if they were not placebo-controlled
or their outcomes did not consider efficacy or
tolerability. The reviewers independently extracted
data on patients’ characteristics, therapeutic
regimens, dosage, trial duration, and outcome
measures. Disagreements, if any, were resolved by
consensus.
Assessment of trial quality
Jadad score, which evaluates studies based on
their description of randomization, blinding, and
dropouts (withdrawals), was used to assess the
methodological quality of the trials [10]. The quality
scale ranges from 0 to 5 points with a low quality
report of score 2 or less and a high quality report
of score at least 3. 
Statistical analysis
Data from selected studies were extracted in the
form of 2 × 2 tables. All included studies were
weighted and pooled. The data were analysed using
StatsDirect (2.7.2). Relative risk (RR) and 95%
confidence intervals (95% CI) were calculated using
Mantel-Haenszel and DerSimonian-Laird methods.
The Cochran Q test was used to test for
heterogeneity. The event rate in the experimental
(intervention) group against the event rate in the
control group was demonstrated using L’Abbe plot
as an aid to explore the heterogeneity of effect
estimates. Funnel plots were used as an indicator
for publication bias.
Results
The electronic searches yielded 1547 items: 241
from PubMed, 20 from Cochrane Central, 446 from
Web of Science, and 840 from Scopus. Of those,
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9 trials were scrutinized in full text. Five reports
were considered ineligible while 4 trials [11-14] were
included in the analysis (Figure 1). All 4 trials
received a Jadad score of 3 or more in assessment
of trial quality (Table I). Patients’ characteristics,
type of MS, mean EDSS before trial, dosage of
natalizumab, and duration of treatment/follow-up
for each study are reported in Table II. This meta-
analysis included 1407 patients with relapsing MS
randomized to receive either natalizumab or
placebo. All trials included in the current meta-
analysis were randomized and double blinded and
patients were diagnosed with relapsing MS
according to EDSS score and magnetic resonance
imaging (MRI) results. 
Efficacy
Pooled RR for at least 1 relapse in 4 trials
including all doses [11-14] was 0.7 with 95% CI of
0.42 to 1.17 and a non-significant RR (p = 0. 17,
Figure 2A). The Cochrane Q test for heterogeneity
indicated that the studies are heterogeneous 
(p = 0.0065, Figure 2B) and could not be
combined; thus, the random effects for individual
and summary of RR were applied. Regression of
normalized effect versus precision for all included
studies for relapse among natalizumab vs. placebo
therapy was 2.02 (95% CI = –5.47 to 9.51, 
p = 0.37), and Kendall’s test on standardized effect
vs. variance indicated tau = 0.67, p = 0.33 
(Figure 2C).
1547 potentially relevant reports identified and screened for retrieval
from electronic search:
241 from PubMed
20 from Cochrane library
446 from Web of Science
840 from Scopus
734 excluded because of duplication
160 excluded because they are reviews
644 reports excluded on the basis of title and
abstract
5 reports excluded upon full text search:
n = 2: other endpoints measured
n = 2: duplication
n = 1: letter
9 reports retrieved
4 eligible randomized controlled clinical trials included in the meta-analysis
Figure 1. Flow diagram of the study selection process
Study Factors and Jadad score
Randomization BlindingW ithdrawals and dropouts Total Jadad score
Polman et al., 2006 2 2 1 5
O’Connor et al., 2004 1 2 1 4
Miller et al., 2003 2 1 0 3
Tubridy et al., 1999 1 2 1 4
Table I. Jadad quality score of randomized controlled trial included in the meta-analysis
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0.5 with a 95% CI of 0.42-0.61, a significant RR 
(p < 0.0001, Figure 3A). The Cochrane Q test for
heterogeneity indicated that the studies are
homogenous (p = 0.98, Figure 3B) and could be
combined but because of few included studies, the
random effects for individual and summary of RR
were applied. Regression of normalized effect vs.
precision for all included studies for clinical response
among natalizumab vs. placebo therapy could not
be calculated because of too few strata.
The summary RR for at least 1 new Gd-
enhancing lesion in 2 trials [11, 13] was 0.22 with 
a 95% CI of 0.05-1.01 and a non-significant RR 
(p = 0.051, Figure 4A). The Cochrane Q test for
heterogeneity indicated that the studies are
heterogeneous (p < 0.0001, Figure 4B) and could
not be combined; thus the random effects for
individual and summary of RR were applied.
Regression of normalized effect vs. precision for all
included studies for clinical response among
natalizumab vs. placebo therapy could not be
calculated because of too few strata.
Mean change in EDSS was reported in 3 trials
[11, 12, 14]; but only 1 trial [12] reports standard
Study Mean  Sex (No.) Type of  EDSS Dosage of  Duration of
age Female Male MSN atalizumabP lacebo natalizumab treatment/
follow-up 
[weeks]
Polman  36 660 282 RRMS 2.3 ±1.2 2.3 ±1.2 300 mg  48
et al., 2006 every 4 weeks
O’Connor  39.5 147 33 RRMS,  1 mg: 4.5 4.5 Single infusion of  45
et al., 2004 SPMS 3 mg: 4.3 1 mg/kg or 3 mg/kg
Miller  43.9 152 61 RRMS,  3 mg: 4.2 4.4 3 mg/kg or 6 mg/kg 24
et al., 2003 SPMS 6 mg: 4.3 every 4 weeks
Tubridy  40.4 46 26 RRMS, SPMS 4.9 4.7 2 infusions of 3 mg/kg 24
et al., 1999 4 weeks apart
Table II. Characteristics of papers included in the meta-analysis
MS – multiple sclerosis, EDSS – Expanded Disability Status Scale, RRMS – relapsing remitting multiple sclerosis, SPMS – secondary progressive
multiple sclerosis
Figure 2A. Individual and pooled relative risk for the
outcome of “at least one relapse” in the studies
considering natalizumab vs. placebo therapy in all
doses
Relative risk meta-analysis (random effects)
Polman et al., 2006
O’Connor et al., 2004
Miller et al., 2003
Tubridy et al., 1999
Combined [random]
0.50 (0.41, 0.62)
1.08 (0.24, 4.96)
0.50 (0.32, 0.79)
1.42 (0.82, 2.53)
0.70 (0.42, 1.17)
Relative risk (95% confidence interval)
0.2                     0.5                1                 2                      5
Figure 2B. Heterogeneity indicators for the outcome
of “at least one relapse” in the studies considering
natalizumab vs. placebo therapy in all doses
Figure 2C. Publication bias indicators for the outcome
of “at least one relapse” in the studies considering
natalizumab vs. placebo therapy in all doses
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Summary RR for at least 1 relapse in 2 trials in
which 3 mg/kg or 6 mg/kg or 300 mg every
4 weeks were administered for therapy [11, 13] wasRelative risk (95% confidence interval)
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Figure 3A. Individual and pooled relative risk for the
outcome of “at least one relapse” in the studies
considering natalizumab vs. placebo therapy in doses
of 3 or 6 mg/kg or 300 mg every 4 weeks
Relative risk meta-analysis plot (random effects)
Relative risk meta-analysis plot (random effects)
Figure 3B. Heterogeneity indicators for the outcome
of “at least one relapse” in the studies considering
natalizumab vs. placebo therapy in doses of 3 or 
6 mg/kg or 300 mg every 4 weeks
L’Abbe plot (symbol size represents sample size)
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Figure 4A. Individual and pooled relative risk for the
outcome of “at least one new Gd-enhancing lesion”
in the studies considering natalizumab vs. placebo
therapy
Figure 4B. Heterogeneity indicators for the outcome
of “at least one new Gd-enhancing lesion” in the
studies considering natalizumab vs. placebo therapy
Study Mean change in EDSS No. of patients with   No. of patients with at least one
at least one relapse new Gd-enhancing lesion
NatalizumabP lacebo NatalizumabP lacebo NatalizumabP lacebo
Polman – – 126/627 126/315 22/627 102/315
et al., 2006
O’Connor  1 mg: –1.5 ±1.5 –1.5 ±1.5 4/117 2/63 – –
et al., 2004 3 mg: –1.3 ±1.4
Miller  3 mg: –0.14 +0.03 27/142 27/71 43/142 48/71
et al., 2003 6 mg: –0.03
Tubridy –0.04 +0.02 18/37 12/35 – –
et al., 1999
Table III. Outcomes
0.11 (0.07, 0.17)
0.45 (0.33, 0.60)
0.22 (0.05, 1.01)
Polman et al., 2006
Miller et al., 2003
Combined [random]
Polman et al., 2006
Miller et al., 2003
Combined [random]
0.50 (0.41, 0.62)
0.50 (0.32, 0.79)
0.50 (0.42, 0.61)
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deviation of the mean (Table III), leaving us with
insufficient data to pool the results. 
Tolerability
Table IV shows the number of patients with any
adverse events, serious adverse events, and
withdrawal because of adverse events in both the
natalizumab group and the placebo group in each
trial. Type of serious and common adverse events,
and cause of death are demonstrated in Table V. As
shown, 3 deaths have been reported from 2 trials
[11, 13]. In Polman’s trial [13], 2 deaths occurred
during the study, both in the natalizumab group.
One patient, who died of malignant melanoma, had
a history of malignant melanoma and had noted 
a new lesion at the time of receiving the first dose
of natalizumab; he had received a total of 5 doses
of natalizumab before receiving a confirmed
diagnosis. A second patient died of alcohol
intoxication after having received 25 doses of
natalizumab. Another death was reported in Miller’s
study [11] because of pleural carcinomatosis
complicated by haemothorax.
The summary RR for any adverse events of
natalizumab vs. placebo therapy among 3 trials [12-
14] was 0.99 with a 95% CI of 0.96-1.01, indicating
a non-significant RR for natalizumab administration
(p = 0.34, Figure 5A). The Cochrane Q test for
heterogeneity indicated that the studies are not
significantly heterogeneous (p = 0.29, Figure 5B)
and the fixed effects for individual and summary of
RR were applied. Regression of normalized effect
vs. precision for all included studies for any adverse
events among natalizumab vs. placebo therapy
could not be calculated because of too few strata.
The summary RR for serious adverse events of
natalizumab vs. placebo therapy in 2 trials [11, 13]
was 0.39 with a 95% CI of 0.29-0.52, indicating 
Study Any adverse events Serious adverse events Death Withdrawal because 
of adverse events
NatalizumabP lacebo NatalizumabP lacebo NatalizumabP lacebo NatalizumabP lacebo
Polman 596/627 300/312 56/627 75/312 2/627 0/312 19/627 6/312
et al.,
2006
O’Connor 106/117 56/63 – – – – – –
et al., 
2004
Miller – – 8/142 7/71 0/142 1/71 7/142 3/71
et al., 
2003
Tubridy 32/37 34/35 – – – – – –
et al., 
1999
Table IV. Adverse events
Study Type of serious adverse events Type of common adverse events Cause of death
NatalizumabP lacebo NatalizumabP lacebo NatalizumabP lacebo
Polman  relapse of  relapse of headache,  headache,  malignant –
et al., multiple   multiple  fatigue,  fatigue,  melanoma,
2006, sclerosis  sclerosis, urinary tract urinary tract alcohol 
cholelithiasis, cholelithiasis infection infection intoxication
need for need for
rehabilitation rehabilitation
therapy therapy
O’Connor – – Headache, headache, – –
et al., pharyngitis, pharyngitis,
2004 nausea dizziness, 
back pain
Miller anaphylactoid serum headache, headache,  – pleural
et al., reaction, sickness infection,  accidental carcinomatosis
2003 serum pharyngitis injury, infection,
sickness myasthenia
Table V. Type of adverse events
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a significant RR for natalizumab administration 
(p < 0.0001, Figure 6A). The Cochrane Q test for
heterogeneity indicated that the studies are
homogeneous (p = 0.41, Figure 6B) but because of
few included studies, the random effects for
individual and summary of RR were applied.
Regression of normalized effect vs. precision for all
included studies for any adverse events among
natalizumab vs. placebo therapy could not be
calculated because of too few strata.
The summary RR for withdrawal due to adverse
events by natalizumab vs. placebo therapy in two
trials [11, 13] was 1.43 with a 95% CI of 0.68-3.02,
indicating a non-significant RR for natalizumab
administration (p = 0.35, Figure 7A). The Cochrane
Q test for heterogeneity indicated that the studies
are homogeneous (p = 0.7131, Figure 7B) and the
random effects for individual and summary of RR
were applied because of few included studies.
Regression of normalized effect vs. precision for all
included studies for any adverse events in
natalizumab vs. placebo therapy could not be
calculated because of too few strata.
Discussion
In the present study, the efficacy and tolerability
of natalizumab were evaluated for the first time by
meta-analysis technique. The results demonstrated
non-priority of natalizumab over placebo in
Figure 5A. Individual and pooled relative risk for the
outcome of “any adverse events” in the studies
considering natalizumab vs. placebo therapy
Figure 5B. Heterogeneity indicators for the outcome
of “any adverse events” in the studies considering
natalizumab vs. placebo therapy
Figure 6A. Individual and pooled relative risk for the
outcome of “serious adverse events” in the studies
considering natalizumab vs. placebo therapy
Figure 6B. Heterogeneity indicators for the outcome
of “serious adverse events” in the studies considering
natalizumab vs. placebo therapy
Relative risk (95% confidence interval)
0.2                                     0.5                                       1        
Relative risk meta-analysis plot (fixed effect)
Polman et al., 2006
O’Connor et al., 2004
Tubridy et al., 1999
Combined [fixed]
0.99 (0.96, 1.02)
1.02 (0.92, 1.16)
0.89 (0.74, 1.03)
0.99 (0.96, 1.01)
Relative risk (95% confidence interval)
0.2                             0.5                      1                        2 
Relative risk meta-analysis plot (random effects)
Polman et al., 
2006
Miller et al., 
2003
Combined [random]
L’Abbe plot (symbol size represents sample size)
E
x
p
e
r
i
m
e
n
t
a
l
 
p
e
r
c
e
n
t
0                 20                40                 60                80               100
Control percent
100
80
60
40
20
0
L’Abbe plot (symbol size represents sample size)
E
x
p
e
r
i
m
e
n
t
a
l
 
p
e
r
c
e
n
t
0                 20                40                60                80               100
Control percent
100
80
60
40
20
0
Shekoufeh Nikfar, Roja Rahimi, Ali Rezaie, Mohammad Abdollahi
0.37 (0.27, 0.51)
0.57 (0.22, 1.47)
0.39 (0.29, 0.52)Arch Med Sci 2, April / 2010 243
preventing relapse or occurrence of new Gd-
enhancing lesions. 
Since different drug regimens were administered
to the patients in the included trials, only two trials
were selected which had similar drug regimens and
thus the analysis for these two trials was repeated
[11, 13]. The results of this analysis showed that
natalizumab was effective in preventing relapse and
occurrence of new Gd-enhancing lesions when
administered in 3 or 6 mg/kg doses every weeks.
As shown in Figures 3A and 2A, the regimen of 3 or
6 mg/kg every 4 weeks seems the most appropriate
because of the 50% reduction in relapse rate. 
In fact, this dose has also been recommended by
the last reported guidelines from the National Insti  -
tute for Health and Clinical Excellence (NICE, UK)
and the TOUCH Natalizumab prescribing programme
for MS.
Contrast-enhanced MRI is a sensitive method
for detecting active lesions. Gd-enhancement is
a marker for blood brain barrier breakdown and
histologically correlates with the inflammatory
phase of lesion development. New lesions in MS
are defined as new enhancements in areas that had
not been seen in a previous scan [15]. As explained
in the introduction, PML is a serious adverse effect
reported from patients who received natalizumab,
but in the present meta-analysis there was no
report of PML from natalizumab. There were two
deaths reported in one of the included studies [13]
in this meta-analysis but it seems they were not
related to natalizumab. As shown in Table V, there
was no significant difference between natalizumab
and placebo in terms of serious and common
adverse events.
According to the NICE guidelines, natalizumab
is mostly recommended for the treatment of
relapsing-remitting multiple sclerosis (RRMS),
although it can be an option for other kinds of MS
and it is recommended to continue with it until the
clinicians consider it appropriate to stop. 
Regarding the updated review of Consensus
Reports related to current basic and escalating
immunomodulatory treatments in MS, the
indication and application of natalizumab should
preferably be handled in an MS centre. In addition,
it should be administered as monotherapy only in
patients with a normal differential blood count with
approval of exclusion for infections [16].
In conclusion, it seems that the best method of
administration of natalizumab in patients with
relapsing MS is 3 or 6 mg/kg every 4 weeks. Current
data on the efficacy and safety of natalizumab
seem to be insufficient and further clinical trials are
needed to obtain more conclusive results [17].
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